PrEP to Put PEP in Your Step: Updates on the Prevention of HIV

After completing this application-based continuing education activity, pharmacists will be able to

• Recognize the role of single agent PEP in improving adherence and its potential drawbacks

• Apply advancements in PrEP delivery to improve patient satisfaction and outcomes in preventing HIV infection

• Identify outcome improvements from newer PrEP and PEP modalities to inform guideline-based clinical decision-making

After completing this application-based continuing education activity, pharmacy technicians will be able to:

• Describe the barriers to adherence for PrEP/PEP and the role of regular patient interactions for improving outcomes

• Apply correct handling, storage, and preparation procedures for oral and injectable PrEP/PEP therapies within the pharmacy workflow

• Distinguish commonly used PrEP and PEP products based on their formulation and route of administration

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy and Pharmaceutical Sciences or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Audi Putri, PharmD

PGY-1 Pharmacy Resident, UConn Health

Farmington, CT

Tyler Vaglivelo, PharmD

PGY-1 Pharmacy Resident, UConn Health

Farmington, CT

Gillian Kuszewski, PharmD

University Director of Pharmacy Residency Programs

Co-Chair of Antimicrobial Stewardship, UConn Health

Farmington, CT

Jeffrey Aeschlimann, PharmD

Associate Professor, UConn School of Pharmacy and Pharmaceutical Sciences

Adjunct Associate Professor, UConn School of Medicine

Farmington, CT

PrEP to Put PEP in Your Step: Updates on the Prevention of HIV
26-018 Pharmacist Post-Test

Learning Objectives:
1. RECOGNIZE the role of single agent PEP in improving adherence and its potential drawbacks
2. OUTLINE advancements in PrEP delivery to improve patient satisfaction and outcomes in preventing HIV infection
3. DESCRIBE outcome improvements from newer PrEP and PEP modalities to inform guideline-based clinical decision-making

1. Which of the following represents an advantage of single tablet regimens demonstrated in HIV nPEP studies?
a. Reduced rates of HIV infections
b. Increase in nPEP completion rate
c. Improvements in adverse effect profiles

2. Which represents a mechanism for lenacapavir that is distinct from other antiretroviral products?
a. Inhibition of capsid core formation
b. Blocking integration into the genome
c. Inhibition of fusion and attachment

3. Which PrEP advancement directly addresses challenges associated with daily pill adherence?
a. Oral FTC/TDF
b. Injectable cabotegravir
c. Post-exposure prophylaxis

4. Which safety consideration is associated with discontinuation of long-acting injectable PrEP?
a. Immediate loss of immune protection
b. Low drug levels increasing resistance risk
c. Increased risk of renal toxicity after stopping

5. Which statement accurately reflects clinical trial findings comparing long-acting injectable PrEP with daily oral PrEP?
a. Injectable PrEP eliminates the need for HIV testing
b. Injectable PrEP demonstrated superior efficacy
c. Injectable PrEP prevents all sexually transmitted infections

6. Which of the following 28-day PEP regimens is preferred in the absence of risk factors for HIV resistance?
a. Dolutegravir/lamivudine
b. Bictegravir/FTC/TAF
c. Raltegravir + FTC/TDF

PrEP to Put PEP in Your Step: Updates on the Prevention of HIV
26-018 Pharmacy Technician Post-Test

Learning Objectives:
1. DESCRIBE the barriers to adherence for PrEP/PEP and the role of regular patient interactions for improving outcomes
2. DETAIL correct handling, storage, and preparation procedures for oral and injectable PrEP/PEP therapies within the pharmacy workflow
3. RECOGNIZE commonly used PrEP and PEP products based on their formulation and route of administration

1. Which storage requirement applies to oral FTC/TAF used for PrEP?
a. Store at room temperature to preserve potency
b. Refrigerate after opening to maintain stability
c. Freeze until dispensing to prevent degradation

2. Which handling step is appropriate when preparing long-acting injectable cabotegravir for administration?
a. Store the vial refrigerated in the original carton
b. Freeze the medication until immediately before use
c. Shake vigorously immediately before injection

3. Which option correctly matches a PrEP medication with its formulation and dosing schedule?
a. Cabotegravir: daily oral tablet taken with food
b. Lenacapavir: subcutaneous injection administered every 6 months
c. FTC/TDF: intramuscular injection administered every 2 months

4. For a patient being initiated on PEP with bictegravir/FTC/TAF, what recommendation can you provide regarding the use of pill organizers?
a. Seven days of medication may be kept outside of the container at a time
b. Do not put the bictegravir/emtricitabine/tenofovir into a pill organizer
c. Avoid using pill organizers due to the short duration of treatment

5. Which HIV nPEP product is available as weekly dosing cards?
a. FTC/TDF
b. Bictegraivr/FTC/TAF
c. Dolutegravir/FTC/TDF

6. Why is patient interaction and education important for individuals prescribed nPEP?
a. The low likelihood of completing nPEP courses
b. High rates of nPEP therapy acceptance by patients
c. Pharmacist-administered injectables are used for nPEP

Learning Objectives

Accreditation Statements

Disclosure of Discussions of Off-label and Investigational Drug Use

Faculty

Faculty Disclosure

CONTENT

Content

Pharmacist Post Test (for viewing only)

Pharmacy Technician Post Test (for viewing only)